✦ LIBER ✦

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors

✍ Scribed by Michael G. Martin; John F. DiPersio; Geoffrey L. Uy

Book ID: 107615974
Publisher: PAGEPress Publications
Year: 2009
Tongue: English
Weight: 228 KB
Volume: 3
Category: Article
ISSN: 1970-5557
DOI: 10.1007/s12156-009-0004-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

STI571, a tyrosine kinase inhibitor for

STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy

✍ Michael J. Mauro; Michael E. O'Dwyer; Brian J. Druker 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 66 KB

Molecular diagnosis and monitoring in th

Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

✍ Joyce Ou; Jo-Anne Vergilio; Adam Bagg 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

## Abstract The well‐established molecular pathogenesis of chronic myelogenous leukemia (CML) and its consequences for laboratory testing and clinical management illustrate a classic paradigm for the importance of molecular diagnostics in targeted drug therapy. The success of the tyrosine kinase in

Front-Line Therapy With Second-Generatio

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

✍ Jabbour, E.; Kantarjian, H. M.; O'Brien, S.; Shan, J.; Quintas-Cardama, A.; Garc 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 126 KB

Complexity of BCR-ABL kinase domain muta

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

✍ Dushyant Verma; Carmen Fava; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

The tyrosine-kinase inhibitor imatinib i

The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22)

✍ Neumann, F; Poelitz, A; Hildebrandt, B; Fenk, R; Haas, R; Royer-Pokora, B; Germi 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 88 KB

The effect of interleukin 11 on thromboc

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Ahmed Aribi; Hagop Kantarjian; Charles Koller; Deborah Thomas; Stefan Faderl; Gu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views